Cathaline den Besten

发表

Impurities in Oligonucleotide Drug Substances and Drug Products.

S. Henry, A. Teasdale, J. Foy, 2017, Nucleic acid therapeutics.

Therapy with 2′-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption

R. Masereeuw, M. Wilmer, T. Nieskens, 2019, Molecular therapy. Nucleic acids.

The Pharmacokinetics of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy.

N. Datson, J. V. van Deutekom, S. Bosgra, 2019, Nucleic acid therapeutics.

Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors.

Chris Oostenbrink, Natalia Markova, Jennifer Venhorst, 2011, European journal of medicinal chemistry.

Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass Spectrometry

Babak Basiri, C. Hassan, M. Bartlett, 2019, Molecular therapy. Nucleic acids.

The liver, kidney, and thyroid toxicity of chlorinated benzenes.

P. van Bladeren, R. Beems, C. den Besten, 1991, Toxicology and applied pharmacology.

The involvement of primary and secondary metabolism in the covalent binding of 1,2- and 1,4-dichlorobenzenes.

P. van Bladeren, I. Rietjens, I. Rietjens, 1992, Chemico-biological interactions.

Comparative biotransformation of hexachlorobenzene and hexafluorobenzene in relation to the induction of porphyria.

P. van Bladeren, B. van Ommen, I. Rietjens, 1995, European journal of pharmacology.

Cytochrome P450-catalyzed oxidation of halobenzene derivatives.

P. van Bladeren, I. Rietjens, C. den Besten, 1997, Chemical research in toxicology.

Impurities in Oligonucleotide Drug Substances and Drug Products.

S. Henry, A. Teasdale, J. Foy, 2017, Nucleic acid therapeutics.